Viral Hepatitis — Viva Defence

Opening statement (SASPOP, delivered aloud)

"Mr Tran is a 45-year-old man with newly diagnosed chronic hepatitis B, almost certainly acquired perinatally in an endemic country, presenting with fluctuating ALT over 18 months — a pattern that suggests immune-active disease rather than a stable inactive carrier state. He is asymptomatic. His main problems are: first, establishing his disease phase and fibrosis stage to answer the central question — treat now or monitor; second, his risk of progressive liver injury and hepatocellular carcinoma, which exists even without cirrhosis given his age and region of birth; third, the infections that travel with HBV — HDV, HCV and HIV — which I must exclude; and fourth, the psychological and social burden of a stigmatised diagnosis, including protecting his family. I would like to phase his disease, stage his liver, and then defend a treatment and surveillance plan with him." [1] [3]

Structured problem list

1. Chronic HBV, phase unassigned — fluctuating ALT 38–118 U/L over 18 months is the signature of intermittent immune attack on infected hepatocytes; I need HBeAg/anti-HBe and serial HBV DNA to separate immune-active from reactivation-phase disease [3].
2. Fibrosis stage unknown — the third axis of the treatment decision; transient elastography, with APRI/FIB-4 as backup [2].
3. HCC risk — Asian male over 40: he qualifies for 6-monthly ultrasound surveillance even without cirrhosis [5].
4. Coinfection screen incomplete — anti-HDV (mandatory once in every HBsAg-positive patient), anti-HCV, HIV [8].
5. Family and household exposure — his wife and children need testing and vaccination if susceptible; his mother and siblings warrant screening given likely perinatal acquisition [1].
6. Stigma and health literacy — 'having a virus' needs reframing into a manageable chronic condition with a plan, in his language, with written supports [3].

Integrated management plan

• Phase and stage: HBeAg/anti-HBe, HBV DNA, full liver panel, transient elastography; ultrasound as the baseline HCC screen [1].
• Treatment decision by thresholds: if his ALT is confirmed above twice the upper limit of normal with DNA above 20,000 IU/mL (HBeAg-positive) or above 2,000 IU/mL (HBeAg-negative), or if he has significant fibrosis, I would start a high-barrier nucleos(t)ide analogue — tenofovir or entecavir — and frame it honestly as long-term suppression, not cure [1] [2].
• If thresholds are not met: structured monitoring — ALT and DNA every 3–6 months — with explicit criteria for revisiting treatment, rather than discharge [2].
• Surveillance: enrol him in 6-monthly ultrasound now, on age-and-region criteria, and continue regardless of treatment status, because suppression attenuates but does not abolish HCC risk [5].
• Agent selection: tenofovir disoproxil if kidneys and bones are unremarkable; tenofovir alafenamide or entecavir if eGFR is reduced or bone disease is present — TAF matched TDF for efficacy with smaller renal and bone effects in phase 3 trials [4].
• Family plan: test and vaccinate household and sexual contacts; screen first-degree relatives; document in the letter to the GP [1].
• The person: address stigma directly — he is well, the virus is manageable, and the plan is prevention; use an interpreter if needed and involve community hepatitis services [3].

Probing questions with model answers

"His ALT is 88 U/L today and DNA is 45,000 IU/mL. Treat or watch?" — "88 U/L is above twice the upper limit of normal for a man, and with DNA above threshold this is immune-active disease meeting AASLD criteria — I would treat, after confirming the fibrosis stage and repeating the ALT once to confirm persistence. If the ALT came back below twice normal, he enters the grey zone: then the elastography result decides — significant fibrosis tips me to treatment, minimal fibrosis to 3-monthly monitoring." [1] [2]

"Why not just watch him? He feels fine." — "Because HBV injures the liver through the immune response, not through symptoms — he feels fine precisely while the inflammation scars his liver. The fluctuating ALT tells me the war is active now; treatment suppresses the virus, quiets the inflammation, and reduces progression to cirrhosis and HCC. Long-term tenofovir data even show regression of established fibrosis. Feeling well is not a reason to watch; it is the norm in chronic HBV." [3] [1]

"What are you aiming for — can you cure him?" — "Honesty matters here. Nucleos(t)ides suppress replication profoundly but cccDNA persists in hepatocytes, so the realistic goal is maintained DNA suppression with normalised ALT. HBeAg seroconversion, if he is HBeAg-positive, is a milestone that can eventually allow a monitored stop after consolidation. HBsAg loss is the functional cure — rare, a few percent per year — and I would not promise it. Framing therapy as indefinite from day one protects adherence." [1] [2]

"Which surveillance does he need, and why does he qualify without cirrhosis?" — "Six-monthly liver ultrasound, because AASLD enrols non-cirrhotic chronic HBV patients from defined risk groups — Asian men from 40, Asian women from 50, people of African ancestry from 20, and first-degree family history of HCC. HBV integrates into the hepatocyte genome and drives HCC without cirrhosis, and the Zhang randomised trial showed 6-monthly ultrasound-based screening reduced HCC mortality by 37%." [5] [6]

"He needs chemotherapy for lymphoma in five years' time. What changes?" — "That is a reactivation emergency prevented in advance: anti-CD20 regimens in an HBsAg-positive patient are the highest-risk tier. He would start or continue entecavir or tenofovir prophylaxis before cycle one and continue 12 months beyond the last rituximab dose, with DNA and ALT monitoring through that window. The key is that screening happened years before the chemotherapy — which is exactly what today's workup achieves." [7]

"Anything you must not forget today?" — "Two tests and two conversations. The tests: anti-HDV — a flare in a suppressed patient is delta until proven otherwise, and he has never been screened — and HCV/HIV serology. The conversations: his family needs testing and vaccination, and I need to hear what this diagnosis means to him, because stigma kills follow-up faster than the virus kills livers." [8] [1]

Communication points

• Reframe the diagnosis: a common, manageable chronic infection with effective suppression and surveillance — not a death sentence and not a mark of shame [3].
• Name the indefinite nature of therapy before starting it — adherence collapses when patients discover year three was never going to be the last [1].
• Deliver the family plan without blame: perinatal acquisition means his mother gave him the virus unknowingly; the task is to protect the next generation, not assign fault [1].